Free Trial
NASDAQ:PLUR

Pluri 11/12/2024 Earnings Report

Pluri logo
$4.95 -0.46 (-8.50%)
Closing price 07/18/2025 03:34 PM Eastern
Extended Trading
$4.66 -0.29 (-5.86%)
As of 07/18/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pluri EPS Results

Actual EPS
-$1.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pluri Revenue Results

Actual Revenue
$0.33 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pluri Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Pluri's next earnings date is estimated for Tuesday, September 16, 2025, based on past reporting schedules.

Conference Call Resources

Pluri Earnings Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
Pluri Inc. reschedules 2025 annual meeting
See More Pluri Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pluri? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pluri and other key companies, straight to your email.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company dedicated to the development, manufacturing and commercialization of off-the-shelf cell therapy products based on proprietary placental-expanded (PLX) cell lines. Leveraging a three-dimensional cell expansion platform, the company generates PLX cells—mesenchymal-like cells derived from full-term placenta—which exhibit immunomodulatory, pro-angiogenic and anti-inflammatory properties. Pluri’s pipeline includes PLX-PAD for the treatment of critical limb ischemia, muscle regeneration and orthopedic conditions; PLX-R18 targeting hematopoietic recovery following radiation exposure; and PLX-COVID-19 for acute respiratory distress syndrome associated with viral infections.

Headquartered in Haifa, Israel, with additional operations in the United States, Pluri operates a fully integrated, cGMP-compliant manufacturing facility capable of producing large-scale cell therapy batches in bioreactors of up to 60,000 liters. This scalable infrastructure underpins the company’s strategy to advance multiple clinical programs in parallel, including ongoing Phase II and Phase III studies across North America and Europe. Pluri has established strategic collaborations with governmental agencies, research institutions and industry partners to support accelerated development through regulatory pathways such as the U.S. FDA’s regenerative medicine advanced therapy (RMAT) designation.

Founded in 2001, the company completed its initial public offering on the Nasdaq under the ticker PLUR in early 2024 following the merger of Pluristem Therapeutics and Pluri Biotechnology. Under the leadership of Chief Executive Officer Tal Vaks, Pluri is focused on translating its platform technology into safe, scalable therapies addressing unmet medical needs in cardiovascular, hematological and respiratory indications. With a multicultural team of scientists and industry veterans, Pluri aims to deliver affordable, off-the-shelf cell therapies that can be shipped directly to treatment centers worldwide.

View Pluri Profile

More Earnings Resources from MarketBeat